An update from Novartis ( (NVS) ) is now available.
Novartis announced that the FDA has granted accelerated approval for Vanrafia, a selective endothelin A receptor antagonist, for reducing proteinuria in adults with primary IgA nephropathy (IgAN). This approval marks a significant milestone in kidney disease treatment, as Vanrafia can be integrated into existing care plans without a REMS requirement. The approval is based on interim results from the Phase III ALIGN study, which showed a 36.1% reduction in proteinuria compared to placebo. This is the third FDA approval for Novartis’s renal portfolio within a year, positioning the company as a leader in kidney care transformation.
More about Novartis
Novartis is a global healthcare company based in Switzerland, primarily focused on pharmaceuticals and biotechnology. The company is known for its innovative treatments in various therapeutic areas, including oncology, cardiology, and nephrology, aiming to transform patient care through groundbreaking therapies.
YTD Price Performance: 17.28%
Average Trading Volume: 2,269,867
Technical Sentiment Signal: Strong Sell
Current Market Cap: $213.6B
For detailed information about NVS stock, go to TipRanks’ Stock Analysis page.